Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema – A Single Center Study

References

• Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346–354. doi:10.1007/s11892-012-0283-6
   PubMed Web of Science ®Google Scholar
• Adan A, Cabrera F, Figueroa MS, et al. Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (ILUVIEN((R))) and follow-up considerations/recommendations. Clin Ophthalmol. 2020;14:2091–2107. doi:10.2147/OPTH.S252359
   PubMed Web of Science ®Google Scholar
• Coelho J, Malheiro L, Melo Beirao J, Meireles A, Pessoa B. Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes. Clin Ophthalmol. 2019;13:1751–1759. doi:10.2147/OPTH.S201611
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–269. doi:10.1001/jamaophthalmol.2017.6565
   PubMed Web of Science ®Google Scholar
• Estebainha R, Goldhardt R, Falcao M. A new approach for diabetic macular edema treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes. Curr Ophthalmol Rep. 2020;8(1):1–10. doi:10.1007/s40135-020-00225-1
   PubMedGoogle Scholar
• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132. doi:10.1016/j.ophtha.2012.04.030
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–1394. doi:10.1016/j.ophtha.2015.03.024
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR; Diabetic Retinopathy Clinical Research N. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Deuchler SK, Schubert R, Singh P, et al. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2537–2547. doi:10.1007/s00417-00022-05564-00412
   PubMed Web of Science ®Google Scholar
• Habib MS. ILUVIEN((R)) technology in the treatment of center-involving diabetic macular edema: a review of the literature. Ther Deliv. 2018;9(8):547–556. doi:10.4155/tde-2018-0006
   PubMed Web of Science ®Google Scholar
• Messenger WB, Beardsley RM, Flaxel CJ. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema. Drug Des Devel Ther. 2013;7:425–434. doi:10.2147/DDDT.S44427
   PubMed Web of Science ®Google Scholar
• Alimera Sciences Limited. Iluvien summary of product characteristics. Available from: https://www.medicines.org.uk/emc/product/3061/smpc. Accessed March 19, 2024.
   Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117(7):1393–1399 e1393. doi:10.1016/j.ophtha.2009.11.024
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–587. doi:10.1016/j.ophtha.2012.09.014
   PubMed Web of Science ®Google Scholar
• Alfaqawi F, Lip PL, Elsherbiny S, Chavan R, Mitra A, Mushtaq B. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye (Lond). 2017;31(4):650–656. doi:10.1038/eye.2016.301
   PubMed Web of Science ®Google Scholar
• Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Ther. 2015;4(1):51–58. doi:10.1007/s40123-015-0028-0
   PubMedGoogle Scholar
• Fusi-Rubiano W, Mukherjee C, Lane M, et al. Treating diabetic macular oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien) at 2 years. BMC Ophthalmol. 2018;18(1):62. doi:10.1186/s12886-018-0726-1
   PubMed Web of Science ®Google Scholar
• Meireles A, Goldsmith C, El-Ghrably I, et al. Efficacy of 0.2 mug/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye (Lond). 2017;31(5):684–690. doi:10.1038/eye.2016.303
   PubMed Web of Science ®Google Scholar
• Pessoa B, Coelho J, Correia N, Ferreira N, Beirao M, Meireles A. Fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN(R)) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018;59(2):68–75. doi:10.1159/000484091
   PubMed Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit G. Real-world experience with 0.2 mug/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond). 2017;31(12):1707–1715. doi:10.1038/eye.2017.125
   PubMed Web of Science ®Google Scholar
• Rehak M, Busch C, Unterlauft JD, Jochmann C, Wiedemann P. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Acta Diabetol. 2020;57(4):469–478. doi:10.1007/s00592-019-01439-x
   PubMed Web of Science ®Google Scholar
• Carneiro A, Meireles A, Castro Sousa JP, Teixeira C. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN(®) clinical evidence study in Portugal. Ther Adv Ophthalmol. 2020;12:2515841420917768. doi:10.1177/2515841420917768
   Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635 e622. doi:10.1016/j.ophtha.2010.12.028
   PubMed Web of Science ®Google Scholar
• Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study. Ophthalmology. 2022;129(6):605–613. doi:10.1016/j.ophtha.2022.01.015
   PubMed Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J. Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye (Lond). 2022;36(5):1012–1018. doi:10.1038/s41433-021-01542-w
   PubMed Web of Science ®Google Scholar
• Quhill H, Quhill F. Real-Life ILUVIEN (Fluocinolone Acetonide) case study: rapid drying of the macula and improved vision within 2 years after therapy initiation. Case Rep Ophthalmol. 2016;7(3):301–307. doi:10.1159/000452883
   PubMedGoogle Scholar
• Pessoa B, Castro C, Ferreira A, et al. Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 microg/day fluocinolone acetonide implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema. Ophthalmic Res. 2022;65(3):310–320. doi:10.1159/000520411
   PubMed Web of Science ®Google Scholar
• Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond). 2015;29(9):1115–1130. doi:10.1038/eye.2015.110
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C; Group IRSSI. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2019;103(8):1072–1077. doi:10.1136/bjophthalmol-2018-312284
   PubMed Web of Science ®Google Scholar
• Khoramnia R, Peto T, Koch F, et al. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. Br J Ophthalmol. 2022;15(321415):2022–321415.
   Google Scholar
• Nurozler Tabakci B, Unlu N. Corticosteroid Treatment in Diabetic Macular Edema. Turk J Ophthalmol. 2017;47(3):156–160. doi:10.4274/tjo.56338
   PubMedGoogle Scholar